A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus (original) (raw)

• NIH. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10–12, 2002). Gastroenterology 123, 2082–2099 (2002).
• NIH. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens. State Sci. Statements 19, 1–46 (2002).
• El-Serag, H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264–1273 e1 (2012).
  Article PubMed Google Scholar
• European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 32 (suppl. 1), 2–8 (2012).
  Article CAS Google Scholar
• Sarrazin, C., Hezode, C., Zeuzem, S. & Pawlotsky, J.M. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56 (suppl. 1), S88–S100 (2012).
  Article CAS PubMed Google Scholar
• Ciesek, S. & Manns, M.P. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat. Rev. Gastroenterol. Hepatol. 8, 69–71 (2011).
  Article PubMed Google Scholar
• Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338–1345 (2010).
  Article CAS PubMed Google Scholar
• Thomas, D.L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment–induced viral clearance. Nature 461, 399–401 (2009).
  Article CAS PubMed Google Scholar
• Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41, 1100–1104 (2009).
  Article CAS PubMed Google Scholar
• Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105–1109 (2009).
  Article CAS PubMed Google Scholar
• Kotenko, S.V. et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69–77 (2003).
  Article CAS PubMed Google Scholar
• Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63–68 (2003).
  Article CAS PubMed Google Scholar
• Marcello, T. et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887–1898 (2006).
  Article PubMed Google Scholar
• Robek, M.D., Boyd, B.S. & Chisari, F.V. λ interferon inhibits hepatitis B and C virus replication. J. Virol. 79, 3851–3854 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Muir, A.J. et al. Phase 1b study of pegylated interferon λ1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52, 822–832 (2010).
  Article CAS PubMed Google Scholar
• Kempuraj, D. et al. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. Int. J. Immunopathol. Pharmacol. 17, 103–106 (2004).
  Article CAS PubMed Google Scholar
• Zhou, Z. et al. Type III interferon (IFN) induces a type I IFN–like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81, 7749–7758 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Honda, M. et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139, 499–509 (2010).
  Article CAS PubMed Google Scholar
• Marukian, S. et al. Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology 54, 1913–1923 (2011).
  Article CAS PubMed Google Scholar
• Dill, M.T. et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140, 1021–1031 (2011).
  Article CAS PubMed Google Scholar
• Urban, T.J. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888–1896 (2010).
  Article CAS PubMed Google Scholar
• Phillips, J.E. & Corces, V.G. CTCF: master weaver of the genome. Cell 137, 1194–1211 (2009).
  Article PubMed PubMed Central Google Scholar
• Rosenbloom, K.R. et al. ENCODE whole-genome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res. 40, D912–D917 (2012).
  Article CAS PubMed Google Scholar
• Shyu, A.B., Wilkinson, M.F. & van Hoof, A. Messenger RNA regulation: to translate or to degrade. EMBO J. 27, 471–481 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Trivella, D.B., Ferreira-Junior, J.R., Dumoutier, L., Renauld, J.C. & Polikarpov, I. Structure and function of interleukin-22 and other members of the interleukin-10 family. Cell Mol. Life Sci. 67, 2909–2935 (2010).
  Article CAS PubMed Google Scholar
• Gad, H.H. et al. Interferon-λ is functionally an interferon but structurally related to the interleukin-10 family. J. Biol. Chem. 284, 20869–20875 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Yoon, S.I., Logsdon, N.J., Sheikh, F., Donnelly, R.P. & Walter, M.R. Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J. Biol. Chem. 281, 35088–35096 (2006).
  Article CAS PubMed Google Scholar
• Yoon, S.I. et al. Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure 18, 638–648 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• International HapMap Consortium. The International HapMap Project. Nature 426, 789–796 (2003).
• 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010).
• Conjeevaram, H.S. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131, 470–477 (2006).
  Article CAS PubMed Google Scholar
• Di Bisceglie, A.M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359, 2429–2441 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Shebl, F.M. et al. IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J. Infect. Dis. 204, 1843–1847 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Vlahov, D. et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res. Monogr. 109, 75–100 (1991).
  CAS PubMed Google Scholar
• Thompson, A.J. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139, 120–129 e18 (2010).
  Article CAS PubMed Google Scholar
• Howell, C.D. et al. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J. Hepatol. 56, 557–563 (2012).
  Article CAS PubMed Google Scholar
• Smith, K.R. et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 3, 57 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Fischer, J. et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 55, 1700–1710 (2012).
  Article CAS PubMed Google Scholar
• Jo, J. et al. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136, 1391–1401 (2009).
  Article CAS PubMed Google Scholar
• Dill, M.T. et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140, 1021–1031 (2011).
  Article CAS PubMed Google Scholar
• Asahina, Y. et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 55, 20–29 (2012).
  Article CAS PubMed Google Scholar
• Onomoto, K. et al. Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS ONE 6, e19799 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 105, 7034–7039 (2008).
  Article PubMed PubMed Central Google Scholar
• Katsounas, A., Schlaak, J.F. & Lempicki, R.A. CCL5: a double-edged sword in host defense against the hepatitis C virus. Int. Rev. Immunol. 30, 366–378 (2011).
  Article CAS PubMed Google Scholar
• Tappero, G. et al. Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. Ital. J. Gastroenterol. Hepatol. 29, 148–154 (1997).
  CAS PubMed Google Scholar
• Smeyne, R.J. et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature 363, 166–169 (1993).
  Article CAS PubMed Google Scholar
• Kang, S.M. et al. c-Fos regulates hepatitis C virus propagation. FEBS Lett. 585, 3236–3244 (2011).
  Article CAS PubMed Google Scholar
• Okamura, K., Feuk, L., Marques-Bonet, T., Navarro, A. & Scherer, S.W. Frequent appearance of novel protein-coding sequences by frameshift translation. Genomics 88, 690–697 (2006).
  Article CAS PubMed Google Scholar
• White, S.H. The evolution of proteins from random amino acid sequences: II. Evidence from the statistical distributions of the lengths of modern protein sequences. J. Mol. Evol. 38, 383–394 (1994).
  Article CAS PubMed Google Scholar
• Uccellini, L. et al. HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology 56, 86–94 (2012).
  Article CAS PubMed Google Scholar
• Chu, T.W. et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 142, 790–795 (2012).
  Article CAS PubMed Google Scholar
• Sonneveld, M.J. et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 142, 513–520 e1 (2012).
  Article CAS PubMed Google Scholar
• Lampertico, P. et al. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology published online; doi:10.1002/hep.25749 (2 April 2012).
• Davar, D., Tarhini, A.A. & Kirkwood, J.M. Adjuvant therapy for melanoma. Cancer J. 18, 192–202 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791–796 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Dickensheets, H.L., Venkataraman, C., Schindler, U. & Donnelly, R.P. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc. Natl. Acad. Sci. USA 96, 10800–10805 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Pepe, M.S. The Statistical Evaluation of Medical Tests for Classification and Prediction (Oxford University Press, Oxford, 2003).